CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)
$39.67 0.14 (0.3542%)
Analysed CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) News Sources
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
16-04-2026
fool.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and More
13-04-2026
247wallst.com
Looks Like M&A Week in 3 Different Sectors
08-04-2026
fool.com
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
06-04-2026
yahoo.com
Eli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story
05-04-2026
yahoo.com
Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster”
04-04-2026
yahoo.com
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience
02-04-2026
marketbeat.com
Eli Lilly (LLY) to Acquire Centessa Pharmaceuticals in $7.8B Deal
02-04-2026
yahoo.com
Eli Lilly (LLY) Stock Trades Up, Here Is Why
02-04-2026
yahoo.com
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
01-04-2026
yahoo.com
What is the current price of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)?
The current price of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) is $39.67.
CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) absolute price change since previous trading day?
The absolute price change of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) since the previous trading day is $0.14.
CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) percentage price change since previous trading day?
The percentage price change of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) since the previous trading day is 0.3542%.
What is the most recent average sentiment score for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)?
The most recent average sentiment score for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)?
The most recent sentiment for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) is .
SEC-8K** Filing Available For CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.